NCT05994365 - Study of Anlotinib Hydrochloride Capsules in the Treatment of Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma | Biotech Hunter

Enrollment

380

Participants

Timeline

Start Date

August 31, 2023

Primary Completion Date

August 31, 2027

Study Completion Date

December 31, 2028

Conditions

Thyroid Neoplasms

Interventions

DRUG

Anlotinib Hydrochloride Capsule

Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor that inhibits both tumor angiogenesis and tumor cell proliferation.

Trial Locations (3)

RECRUITING

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing

RECRUITING

Tianjin People's Hospital, Tianjin

RECRUITING

Tianjin Cancer Hospital, Tianjin